19
Biotecnol Corporate Presentation Therapies for life José Luís Moreira, Ph.D., MBA Chief Financial Officer & Chief Operational Officer
| Date post: | 22-Mar-2016 |
| Category: |
Documents |
| Upload: | oeiras-invest |
| View: | 237 times |
| Download: | 2 times |
Biotecnol Corporate Presentation
Therapies for life
José Luís Moreira, Ph.D., MBA Chief Financial Officer & Chief Operational Officer
Development of new drugs
Development of new drugs
Research
institutions
Development of new drugs
Multinational pharma corps.
Development of new drugs
Multinational pharma corps.
Development of new drugs
Biotec sme’s
Biotecnol
Core Business
7
proprietary products
strategy (long term)
services
tactics (short term)
new pharma products
oncology
MoABs
Biotecnol
● improved products to known targets
● new products to new targets
2003 – ...
technologies platforms
partnerships
processes
products
know-how
● services to other
companies
● production of their own
products
● optimization of
production process
● as a service supply or in
partnership
Biotecnol
hepathology
8
Core Business
1998 – ...
Corporate Organization
inc
sa
sasa
www.biotecnol.com www.rodonbiologics.com
Rodon Biologics
Corporate Organization
New Brunswick, NJ (USA)
Oeiras (Portugal)
Non Tribody services to 3rd parties
Subcontracted Tribody
development services
Potential Biotecnol SA competitors
Highly qualified and experienced
scientists
Fully equipped laboratories
Out-licensing and own Tribody pipeline
Rodon Biologics
Tribody Platform IP US management Know-How Protocols SOP’s Commercial and
R&D contracts
Third party outsourcing
Site in Oeiras, PT
• Process development and manufacturing • Quality Control System
Site in New Brunswick, NJ
• Preclinical development
• Future clinical development
Corporate Organization
State of the art R&D centre
• First Portuguese biopharmaceutical company to establish its activity outside a public R&D institute and become fully independent • Full internal capabilities for biological products development and manufacturing
State of the art R&D centre
Effective process development
PROCESS
DEVELOPMENT
Economics
Business
Technology
Manufacturing
Engineering
Scale-up
Quality Control
Quality Assurance
Regulatory Affairs Supply Chain and Logistics
Naples University
Collaboration and technology licensing
3rd party services
3rd party services
IL-13
Cardiotrophin1
VB6-845-CL
GMCFS
Interferon
Bavituximab
ACE393
NS3
Uvidem®
transplants
oncology
stroke
ACV
HCV
vaccine
Hepatitis C
Anti-Hsp90
FastScreen
metastatic melanoma
ADC-1004 Stroke, trauma
Product Partner Indication R&D Pre-clinic Phase
I Phase
III Phase
II
Pro.insulin Retinitis pigmentosa
Tribody Platform
dual antigen target molecules
single antigen target molecules
CD19 CD19 CD20 CD20 XX
CD3CD3 CD3
CD19 CD19 CD20 CD20 XXCD19 CD19 CD20 CD20 XX
CD3CD3 CD3
CD20CD19
CD3
XCD19
CD3
CD20 X
CD3
CD20CD19
CD3
XCD19
CD3
CD20 X
CD3
CD20CD19
CD3
CD20CD19
CD3
XCD19
CD3
XCD19
CD3
CD20 X
CD3
CD20 X
CD3
19
Contacts
Biotecnol, SA
Lagoas Park
Edifício 7,1º Norte
2741-901 Oeiras
Portugal
Biotecnol Pharmaceuticals, Inc
675 US Highway OneNorth Brunswick, NJ 08902 USA USA
www.biotecnol.com
www.rodonbiologics.com
